Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
February 26, 2026
Earnings Call Speaker Segments
Melissa Jarel
executiveThanks, operator. Hello, everyone. We're glad you could join us for today's Heron Therapeutics call, during which we'll review the company's financial results for both the fourth quarter and the full year that closed on December 31, 2025. Here with me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy, and Engagement. If you're listening in on the conference call, slides can be accessed via the webcast, and once today's call concludes, they'll also be posted on the investor relations section of our website. At the outset, I want to give everyone a quick reminder that forward-looking statements will be made by the company on today's call. Keep in mind that anything we say which does not describe something that already happened qualifies as forward-looking. That includes anything we discuss regarding the company's projections, expectations, plans, beliefs, and future performance — all of which count as forward-looking statements under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995; such statements are based on judgment and analysis as of today, and they carry a number of significant risks and uncertainties that might cause actual results to differ materially from what those forward-looking statements describe. Details about the hazards and unknowns connected to the predictive remarks shared during this call and webcast can be found in the Safe Harbor section of the press release issued today, as well as in Heron's routine periodic submissions to the SEC. Unless legally mandated, Heron does not commit to revising these predictive remarks to account for upcoming occurrences or real results, and has no plans to do so. Having said that, I'll pass things over now to Craig Collard, Heron's Chief Executive Officer.
Craig Collard
executiveThank you, Melissa. Hi, everybody, and thanks for joining our call covering Heron Therapeutics' results for Q4 and the entire 2025 fiscal year. We're excited today to walk you through our financial performance and share commercial updates regarding the business. Let me start by calling out a handful of major wins achieved during the quarter and across all of 2025. Among the biggest was getting our financing across the finish line; that matter had weighed on the company for quite a while, and putting it behind us marks a significant de-risking milestone. Now that a sound capital structure is secured, leadership can focus entirely on commercial execution, expanding our products, and generating durable growth. On top of closing that financing, the Heron team posted robust operational and financial results during Q4 and throughout 2025. Across the entire year, total net revenues came in at roughly $155 million, and adjusted EBITDA reached $14.7 million, which beat the guidance range we had previously shared of $9 million-$13 million. Our gross margin for the year landed at about 73%, which speaks to ongoing gains in cost discipline and product mix. Shifting to acute care, we carried out a number of strategic moves during 2025 that reinforced our commercial footing and produced meaningful acceleration as the year drew to a close. Those moves included rolling out the CrossLink Ignite program, an incentive-driven effort built to deepen distributor engagement, bringing forward the Vial Access Needle, or VAN, and putting a new J-code in place for ZYNRELEF, which sharpens reimbursement clarity and enables wider hospital adoption. On the APONVIE side, we built a devoted sales force called the IBM team, tasked solely with APONVIE and CINVANTI in the hospital channel. Notably, APONVIE also earned a place in the just-issued fifth consensus guidelines covering PONV management, which further confirms its clinical worth and strengthens long-term utilization. All through 2025, we told investors to expect an inflection in acute care performance during late Q3 or early Q4. I'm happy to say that arrived sooner than we had internally anticipated. During Q4, ZYNRELEF posted 48% net revenue growth versus Q4 of 2024, and APONVIE climbed 97% across that same stretch. In total, our acute care franchise rose more than 57% year-over-year for the quarter. These figures show that the strategic steps taken in 2025 are producing durable momentum throughout the portfolio. Given a stronger commercial infrastructure, better reimbursement pathways, and growing clinical adoption, we feel well positioned to keep up this trajectory as we head into 2026. As we keep witnessing a favorable shift in acute care product growth, our approach starting in 2026 and afterward is to speed up expansion of our commercial team in key markets nationwide. These priority geographies show strong success indicators, solid market access, favorable reimbursement dynamics, established CrossLink relationships, and market characteristics resembling our top-performing territories. By directing our investments toward areas where foundational success factors are already present, we can scale more efficiently and maximize near-term commercial productivity. What we're doing here is meant to generate real expansion on the top line. Because of the opportunities in front of us, we're stepping up spending on the commercial side, and that could hold back EBITDA growth for a while. Given how attractive the long-term returns look, we think that spending is justified. When we broaden our reach in areas where we've already gained ground, we can bring revenue in sooner, speed up penetration of those markets, and open the door to a far bigger growth path in later years. What investors should take away is this: careful, well-targeted commercial spending today sets the company up for disproportionate revenue acceleration, better operating leverage, and considerably greater enterprise value as we win a larger portion of the high-opportunity acute care markets. On the development side, we're continuing to move forward the prefilled syringe, or PFS, version of ZYNRELEF. The registration batches went onto stability in Q4 of last year. Before we can submit, we'll have to finish 12 months of stability testing. If we assume a standard four to six-month regulatory review, we'd expect a possible approval around mid to late 2027. Now turning to oncology. Despite mounting competitive pressure, we kept up solid performance with CINVANTI. Across the full year 2025, net revenue from the oncology franchise came in at just over $105 million, a modest 7.8% decrease from 2024. It's important to note that most of that decrease stems from SUSTOL, since we're carrying out the planned wind-down of that product through 2026. CINVANTI on its own has stayed resilient, showing strong customer loyalty and ongoing demand even as the landscape grows more competitive. Before I hand things to Mark Hensley to walk through our commercial performance, I'd like to pause and acknowledge the whole Heron team. Everything we achieved in 2025 happened only because of the effort, dedication, and resilience shown throughout the organization. From our commercial groups executing in the field to our manufacturing, R&D, regulatory, and corporate teams backing every part of our strategy, your hard work comes through in the results we posted this year. Underneath it all is a group of people who turn up each day with focus, urgency, and belief in Heron's mission. I couldn't be prouder of what we did together in 2025, and I'm certain that with this team, we're in a strong position to carry that momentum into 2026 and beyond. To each of you at Heron, thank you for your ongoing effort, your dedication to patients, and your steadfast drive to deliver results. Go ahead, Mark.
Mark Hensley
executiveThanks, Craig. I'll begin with acute care, since we wrapped up the year carrying real momentum there, and afterward I'll end with oncology supportive care. Turning to Slide 6 now. In the fourth quarter, acute care net sales reached $16.3 million, compared with $12.3 million during the third quarter — roughly a 33% gain. ZYNRELEF was the main force behind that sequential improvement. ZYNRELEF net sales climbed to $12.5 million, versus $9.3 million in Q3. APONVIE net sales likewise rose, reaching $3.8 million from $3 million. Measured against the prior year, ZYNRELEF net revenue was up 48%, while APONVIE was up 97%. Taken together, we're pleased with that exit rate and with the momentum we carry into 2026. Though some ordinary quarterly fluctuation can be expected early in the year, our attention stays on execution, and we anticipate performance strengthening as 2026 unfolds. Let me explain what drove ZYNRELEF's sequential momentum. Sharper distributor execution played a major role. In July of 2025, we introduced the CrossLink Ignite program. That sharper focus paid off during the fourth quarter. Given those results, we've chosen to carry the program forward into 2026. We also broadened the set of target accounts that CrossLink concentrates on. At the same time, we lowered friction for hospitals and ASCs; the Vial Access Needle rollout is now finished, and it enhances preparation and handling. A permanent J-code, J0668, is in place, which assists with streamlining reimbursement. More generally, reimbursement keeps getting simpler as hospitals and ASCs become more comfortable with coding and with the changing post-op pain reimbursement landscape, the NOPAIN Act included. Going forward, development continues on the proposed prefilled syringe presentation. Should that succeed, our aim is FDA approval in mid to late 2027. All in all, the narrative holds steady. Additional accounts adopting, fewer obstacles to sustained use, and a process that's more repeatable, which underpins growth continuing over time. APONVIE comes next, where we're establishing a comparable pattern of broadening adoption among hospitals. Demand units were up 101% versus a year ago. The count of ordering accounts kept growing too. On the operational side, we stood up the dedicated APONVIE sales team on July 1, aimed at hospital accounts with high potential; this quarter, we're also announcing a permanent product-specific J-code, J8502, which backs reimbursement clarity. Notably, APONVIE now appears in the just-released fifth consensus guidelines for managing PONV. Our thinking here is simple. Being in the guidelines plus permanent coding lowers friction for hospitals. They additionally help with education on multimodal prophylaxis and coverage that lasts longer. We anticipate that will underpin adoption continuing over time. Last, I'll finish with oncology supportive care, still a key foundation for the company. Oncology supportive care net sales came to $24.2 million for the quarter. Versus a year ago, oncology was down this quarter, mostly a reflection of SUSTOL's persistent decline. CINVANTI stays the franchise's anchor, and with CINVANTI, our focus is generating hospital demand while handling anticipated pricing dynamics on the clinic side. APONVIE and CINVANTI benefit more and more from the same hospital relationships. When we get deeper into anesthesia and pharmacy engagement, what we tend to observe is broader franchise pull-through developing across time. The main takeaway here is that oncology keeps giving us a dependable revenue foundation, even while we handle the pricing pressures and competition we've been expecting. So to close things out, we came out of 2025 carrying obvious momentum in acute care. The quarter-over-quarter lift was driven by ZYNRELEF, helped along by sharper execution, less complicated workflows, distributor alignment via the CrossLink Ignite program, and clearer reimbursement. Hospital adoption kept growing for APONVIE, and our view is that permanent coding plus inclusion in new guidelines will back further gains as time goes on. Supportive care in oncology stays a dependable foundation while we navigate pricing and competitive forces. Looking ahead toward 2026, the goal is to continue scaling the things that are working. Now that the playbook exists, our plan is to start bringing on additional field capacity around the middle of the year, aimed at priority geographies where strong access, reimbursement, and distributor traction are already evident. So with that, I'll hand things over to Ira, who will take you through the financials.
Ira Duarte
executiveThanks, Mark. The results we posted for 2025 highlight just how much headway Heron is making as we reshape where this business is headed commercially, all while keeping a tight grip on our financial discipline. Net product sales across 2025 came to $154.9 million in total, up from what we recorded in 2024, and the main engine behind that was the standout showing from ZYNRELEF, our lead product, which posted 48% revenue growth year over year during the fourth quarter by itself. What matters even more is that we keep steering our mix of products toward the assets with the strongest growth potential, and we're doing so with margins that stay both solid and steady. That pickup in momentum gave us greater conviction about the demand trends underneath it and about the adoption curve that keeps widening throughout our acute care franchise. Meanwhile, we managed all of this expansion without giving up EBITDA profitability — full-year adjusted EBITDA landed at $14.7 million, which is over twice what we delivered the year before and ahead of the guidance we'd set for all of 2025. Reaching that point is a significant milestone. Heron is proving it can expand revenue substantially without letting financial discipline slip. Looking ahead to 2026, we see it as a decisive year. The commercial turning point that started emerging in Q4 2025 keeps gathering strength, and we plan to press that advantage. Our approach calls for staying EBITDA positive during 2026 while directing focused commercial spending that sets up ZYNRELEF and the wider portfolio for still greater growth in the coming years. Those outlays could hold back EBITDA growth in the near term, yet they are intentional, aimed at speeding up our route to durable revenue growth and free cash flow generation in 2027. One thing worth noting: the refinancing we completed last year removed the capital structure overhang that had been holding the business back, giving Heron the financial flexibility required to carry out this next stage of expansion. With a solid balance sheet, a commercial footprint that keeps growing, and real momentum at the product level, we head into 2026 with clarity, confidence, and a strategic plan built to create long-term value for the company. Our guidance for 2026 captures that confidence: net product sales between $173 million and $183 million, and adjusted EBITDA between $10 million and $20 million, which shows we expect to stay profitable through a year of commercial expansion. At this point, we'd like to open the call for any questions.
Serge Belanger
analystHello, and good morning — I appreciate you taking my questions. About the fresh 2026 outlook, could you perhaps walk us through what you're anticipating for the CINV business, which at this point I believe is nearly 95% or so, CINVANTI? As for the NOPAIN Act, ought we still to view that as a favorable push for ZYNRELEF? I saw that I don't believe it was even referenced in the slides among the growth drivers, yet could this continue to be something that assists the franchise down the road? Thank you.
Craig Collard
executiveThanks, Serge. So, on the CINV business, yes, we, as you know, keep believing that we're going to, well, we'll see unit volume expansion. Once more, since the IBM team is now out there promoting it too, we ought to achieve some volume increase on the hospital side, though concurrently, we're going to encounter some price erosion. Even so, sales ought to remain fairly level across the year. As for the NOPAIN Act, I'll hand things over to Mark Hensley.
Mark Hensley
executiveRight, absolutely not. I mean, that's definitely a strong question, and our view is that the NOPAIN Act is going to keep being really advantageous for us. You know, I'd say the bulk of 2025 involved getting providers up to speed on the NOPAIN Act. We definitely see that as a powerful tailwind moving ahead. That, along with ZYNRELEF having a permanent J-code, is going to take away friction for our institutions.
Brandon Folkes
analyst... Hello, thank you very much, and congratulations on everything that's been accomplished. Perhaps beginning with the VAN, could you share where things stand regarding P&T committees, in terms of how the VAN is being rolled out? Is that at the level you want it for 2026, and is it truly just a sales detail fueling this year's growth? Or ought we to consider a sales detail plus access inside the hospital institution acting as a tailwind? Also, if we stay on that subject, are there any takeaways from the VAN rollout that might alter or slightly adjust the potential launch of the prefilled syringe? Or should we view the prefilled syringe rollout as closely resembling the VAN commercial rollout? Thank you.
Mark Hensley
executiveYes, I appreciate the question. Our growth strategy for this year really has two components. The first component is where our Heron employees overlap with CrossLink, where we have the proper resources in our primary targets. That means going deeper into hospitals, correct? At many of our accounts, only a few providers are using ZYNRELEF, yet we have formulary access at those accounts and the ability to spread — to go deeper and wider within them. You'll see us keep doing that. Certainly, the VAN has played a big role in removing what I call friction — those challenges on the preparation side — and that has largely been eliminated. Beyond those accounts, CrossLink is a much bigger organization than we are and has other targets beyond the Heron employees. Those are additional accounts we continue to focus on and grow as well. Regarding how the VAN was rolled out, that actually went remarkably well. I think the transition was largely free of issues as we moved into it. It was simply a matter of winding down the prior supply of the VVS and then rolling into the VAN. There's probably little we would change as we moved into the prefilled syringe launch in terms of strategically how we roll it out. Just managing inventory on both products as we get closer so that we can move quickly once the prefilled syringe is approved and ready.
Brandon Folkes
analystGreat. Thank you very much.
Mark Hensley
executiveYou're welcome.
Carl Byrnes
analystI appreciate you taking the question, and nice work on the progress. So I was hoping to spend a moment discussing the Slayback litigation involving CINVANTI. Unless I'm wrong, that's the very same judge, William Bryson, sitting in the same U.S. District Court of Delaware that issued the ruling in the Fresenius matter. It also appears to me that the statutory framework matches — 505(b)(2), Hatch-Waxman, Orange Book patents — plus formulation range, excipient ratios, pH parameters, that sort of thing. How do you see this litigation resolving, and what's your sense of the timeline? Thanks.
Melissa Jarel
executiveHello, Carl. Melissa Jarel here. I appreciate the question; our confidence in the case we presented at trial is very high. Briefing wrapped up earlier this month, and the matter sits with Judge Bryson; we're waiting on a date for oral argument, though we anticipate a ruling prior to the 30-month stay.
Carl Byrnes
analystGreat. That's perfect. Really useful. I'd like to ask a follow-up, going back to the NOPAIN Act. Could you say a bit more about what your company might be doing, or what other players in the industry are doing, when it comes to building awareness, considering how awareness stands relative to how big the opioid crisis is? Thanks.
Craig Collard
executiveYeah, Carl, I appreciate the question. You know, here's the interesting part. One thing I believe we ran into, and hadn't expected, is that when the NOPAIN Act sort of came out, we figured it would be pretty straightforward and that everyone would know about it and, clearly, would move from what is otherwise a cost, right, in a surgical bundle type of scenario, to something where they actually earn money. There's an incentive in that. What we've discovered is, as we've moved through this, some of the coding, and simply the awareness around it, has moved a little slower. I think it's now moving, you know, a good deal quicker. That caught us somewhat off guard. We're growing some of our team that deals with that, so we can respond to questions and assist with some of that too. That was somewhat unexpected. You know, Mark can maybe jump in on a few things in particular that we're doing that, you know, are building more awareness and helping us on that front.
Mark Hensley
executiveRegarding the industry side you raised in the latter portion of your question — no, it isn't only our company concentrating on NOPAIN and education. As you're surely aware, a number of other sizable firms also hold a real stake in guaranteeing that people know about and grasp the way reimbursement functions. That process isn't intricate; it's actually fairly straightforward. The thing is, many participants in this space need to comprehend it and then pursue that reimbursement. Really, this comes down to awareness more than anything. Still, in the places where we're winning business — the spots we've prioritized and aimed at — those folks know about the NOPAIN Act and get that reimbursement. We're starting to observe a growing number of commercial plans doing the same thing, and I'd say that earlier on, that was part of what held back adoption. Now, though, as we move into the new year, we're seeing far more consistency between commercial and CMS when it comes to NOPAIN.
Carl Byrnes
analystGreat, that's really useful too. So, just one last very quick item, and I apologize if it repeats something. Now that this consensus guidance on PONV has been included, what sort of realistic timeline do you see for it to take effect and make a meaningful difference to how PONV grows? Thanks.
Mark Hensley
executiveYes, so we were definitely very pleased to see what the new guidelines said, and we are confident they will provide a substantial tailwind for PONV. The guidelines are definitely a helpful educational resource for us, particularly when you consider a PONV being brought to P&T for possible approval. In many instances, pharmacy will probably cite those guidelines. Before that, we had strong clinical data. A great deal supports IV aprepitant and how it is used in this setting. The guidelines are strong enough that we think their impact will be considerable. The timeline for that is likely the back half of the year. The cycle for P&T approvals and additions tends to run about six months, so I would not anticipate much effect today. As we continue moving forward across the year, we do think the impact will be significant.
Carl Byrnes
analystExcellent. Thanks again, and congrats.
Mark Hensley
executiveSure.
Kevin Warner
executiveHi, Kevin Warner here. I want to provide some additional perspective building on what Mark said regarding those consensus guidelines. If you will, guidelines truly transform the paradigm—what institutions accept and what we examine. They lend substantial credibility and validity to the information and the data. That goes a long way toward altering clinical decision tools, order sets, and protocols, while also driving adoption over the long term. At the moment, when guidelines first come out, clearly you're going to build awareness and education regarding the clinical impact of PONV and how we ought to be supporting these patients during the acute phase as well as the extended phase. Adoption will be slow initially as people come on board. You'll see what I refer to as soft adoption, where individual providers acknowledge the information and acknowledge best practices, and then you achieve full implementation. Given a guideline's credibility, the consensus statement, the level of evidence, and the quality of evidence contained within the guidelines, it elevates this to all those P&T tables as a necessity for the best patient outcomes. As they work through that, embedding it into order sets and protocols, so that every high-risk patient gets appropriate therapy, that genuinely shifts the trajectory, and you achieve sustainable long-term adoption. Regarding PONV specifically within the guidelines, we felt very pleased with the guidelines and the way they presented the NK1 antagonist class. They really emphasized their long, durable efficacy across that entire phase of post-op recovery for patients, the rapid onset with the IV push of PONV, and the clinical efficacy of the NK1 class alongside a great safety profile. The guidelines will go a long way in terms of bringing credibility when we enter an institution to educate them on best practices for patients. At that point it's not merely product driven. This is a consensus statement from 25 societies endorsing this information. A tremendous driver for the future, and as Mark mentioned, it's probably 6 to 9 months before we roll it out into those order sets and protocols that genuinely change trajectory and sustained growth.
Carl Byrnes
analystExcellent. Appreciate it once more. Thank you very much.
Craig Collard
executiveThanks, operator. I appreciate all of you being with us on today's call. We can't wait to talk with everyone again in the next quarter. Thank you.
Operator
operatorWe appreciate everyone joining us on this call today. That brings the program to its end. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.